DrugPatentWatch Database Preview
Drugs in Development Information for Serelaxin
What is the drug development status for Serelaxin?
Serelaxin is an investigational drug.
There have been 14 clinical trials for Serelaxin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Heart Failure, Hypertension, Portal, and Hypertension. The leading clinical trial sponsors are Novartis Pharmaceuticals, Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, and University of Edinburgh.
There are two US patents protecting this investigational drug and two hundred and fifty-six international patents.
Summary for Serelaxin
| US Patents | 2 |
| International Patents | 256 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Serelaxin
| Title | Sponsor | Phase |
|---|---|---|
| Serelaxin To Lower Portal Pressure | NHS Lothian | Phase 2 |
| Serelaxin To Lower Portal Pressure | Novartis Pharmaceuticals | Phase 2 |
| Serelaxin To Lower Portal Pressure | University of Edinburgh | Phase 2 |
Clinical Trial Summary for Serelaxin
Top disease conditions for Serelaxin
Top clinical trial sponsors for Serelaxin
US Patents for Serelaxin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Serelaxin | Start Trial | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | Corning Incorporated (Corning, NY) | Start Trial |
| Serelaxin | Start Trial | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | Corning Incorporated (Corning, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Serelaxin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Serelaxin | Australia | 2012328780 | 2031-10-25 | Start Trial |
| Serelaxin | Australia | 2013226031 | 2031-10-25 | Start Trial |
| Serelaxin | Australia | 2013226034 | 2031-10-25 | Start Trial |
| Serelaxin | Australia | 2013271436 | 2031-10-25 | Start Trial |
| Serelaxin | Australia | 2013282411 | 2031-10-25 | Start Trial |
| Serelaxin | Australia | 2013352444 | 2031-10-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
